PolyPid Ltd., an Israeli biotechnology company, announced today positive preliminary results of a first-in-man clinical trial with BonyPid. In the study, BonyPid demonstrated a clear, positive signal of effect in bone recovery processes, on bones with contaminated open fractures.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments